Skip to main content
Smart Investors Daily
GO

NASDAQ · GOVX

GeoVax Labs, Inc. New

Healthcare · Biotechnology

$2.02

Up+$0.32 (+18.48%)

Updated Nov 17, 2026, 6:16 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
9.64M
P/E ratio
-0.3
Dividend yield
0.00%
52-week range
$0.16 – $12.50
Volume
7.17M
Avg. volume
794.22K

Price performance · GOVX

GOVX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

GOVX closed at $2.02 after 21 trading sessions, up 787.91% for the selected period.

Last close
$2.02
Period change
+787.91%
Period low
$0.16
Period high
$3.79
Daily close
View OHLC price history
GOVX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$1.76$2.1099$1.505$2.027.17M
Nov 13, 2026$2.20$2.20$1.57$1.70597.71K
Nov 12, 2026$2.10$2.18$1.94$2.04128.4K
Nov 11, 2026$2.96$3.00$1.84$2.16518.23K
Nov 10, 2026$3.408$3.408$2.658$2.67656.35K
Nov 9, 2026$3.72$4.0392$3.3648$3.43220.35K
Nov 6, 2026$3.792$3.7968$3.3432$3.789615.46K
Nov 5, 2026$4.032$4.032$3.432$3.79260.48K
Nov 4, 2026$0.172$0.1738$0.1602$0.168285.82K
Nov 3, 2026$0.168$0.1746$0.1566$0.1641842.62K
Nov 2, 2026$0.175$0.175$0.161$0.163258.81K
Oct 30, 2026$0.1788$0.1848$0.1651$0.1686394.1K
Oct 29, 2026$0.1999$0.20$0.1834$0.1859146.47K
Oct 28, 2026$0.2072$0.2079$0.192$0.1983110.18K
Oct 27, 2026$0.19$0.208$0.19$0.2012185.19K
Oct 26, 2026$0.2032$0.2127$0.1896$0.1944227.11K
Oct 23, 2026$0.2266$0.2271$0.2033$0.206269.38K
Oct 22, 2026$0.2257$0.2299$0.2126$0.2127128.31K
Oct 21, 2026$0.23$0.2345$0.22$0.2322147.63K
Oct 20, 2026$0.23$0.24$0.2204$0.2271190.83K
Oct 19, 2026$0.238$0.2423$0.2262$0.2275130.67K

Latest GOVX news

The latest Smart Investors Daily articles mentioning GOVX.

GOVX research

Overview

Company profile and research snapshot.

Company profile

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
GOVX recent ratings
DateFirmRatingTarget
Sep 15, 2026Noble Capital MarketsOutperform—
Apr 16, 2026D. Boral CapitalHold—
Feb 19, 2026D. Boral CapitalHold—
Jan 21, 2026D. Boral CapitalBuy—
Nov 19, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

seekingalpha.com · Nov 13, 2025

GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript

GeoVax Labs, Inc. ( GOVX ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants David Dodd - Chairman, President & CEO Mark Reynolds - CFO & Corporate Secretary John Sharkey - Vice President of Business Development Conference Call Participants Jonathan Aschoff - ROTH Capital Partners, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Laura Suriel John Vandermosten - Zacks Investment Research, Inc. Presentation Operator Good afternoon, and welcome, everyone, to the GeoVax Third Quarter 2025 Corporate Update Call. My name is Sherry, and I will facilitate today's call.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.